SCHEMBL18674

SCHEMBL18674

O=C(O)CCCCC(=O)OCc1ccccc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.61
MAPK1 P28482 3/20 0.61
L3MBTL1 Q9Y468 2/20 0.61
HTT P42858 1/20 0.61
MAPT P10636 1/20 0.56
RXFP1 Q9HBX9 1/20 0.56
SLC6A3 Q01959 2/20 0.55
HDAC3 O15379 2/20 0.55
HDAC4 P56524 2/20 0.55
HDAC1 Q13547 2/20 0.55
HDAC7 Q8WUI4 2/20 0.55
HDAC2 Q92769 2/20 0.55
HDAC10 Q969S8 2/20 0.55
HDAC11 Q96DB2 2/20 0.55
HDAC8 Q9BY41 2/20 0.55
HDAC6 Q9UBN7 2/20 0.55
HDAC9 Q9UKV0 2/20 0.55
HDAC5 Q9UQL6 2/20 0.55
ADRA1A P35348 1/20 0.55
SMN1; SMN2 Q16637 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8488876 0.98 HTT (0.59) ALDH1A1MAPK1L3MBTL1HTTMAPT
SCHEMBL905777 0.98 HTT (0.59) ALDH1A1MAPK1L3MBTL1HTTMAPT
SCHEMBL2932079 0.98 HTT (0.59) ALDH1A1MAPK1L3MBTL1HTTMAPT
SCHEMBL3335775 0.98 HTT (0.59) ALDH1A1MAPK1L3MBTL1HTTMAPT
SCHEMBL8491249 0.98 HTT (0.59) ALDH1A1MAPK1L3MBTL1HTTMAPT
SCHEMBL8854045 0.98 HTT (0.59) ALDH1A1MAPK1L3MBTL1HTTMAPT
SCHEMBL17004058 0.98 HTT (0.59) ALDH1A1MAPK1L3MBTL1HTTMAPT
SCHEMBL16197784 0.98 HTT (0.59) ALDH1A1MAPK1L3MBTL1HTTMAPT
SCHEMBL9814068 0.98 HTT (0.59) ALDH1A1MAPK1L3MBTL1HTTMAPT
Sebacic Acid SCHEMBL28606878 0.98 HTT (0.59) ALDH1A1MAPK1L3MBTL1HTTMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 380 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240210727-A1 OPHTHALMIC ARTICLES MADE FROM CELLULOSE ESTER COMPOSITIONS HAVING HIGH TOUGHNESS AND DIMENSIONAL STABILITY EASTMAN CHEMICAL COMPANY (US) 2024-06-27 US claimed
EP-4320187-A1 OPHTHALMIC ARTICLES MADE FROM CELLULOSE ESTER COMPOSITIONS HAVING HIGH TOUGHNESS AND DIMENSIONAL STABILITY Eastman Chemical Company (US) 2024-02-14 EP claimed
CN-117178017-A Ophthalmic articles having high toughness and dimensional stability made from cellulose ester compositions 伊士曼化工公司 2023-12-05 CN claimed
WO-2022216473-A1 OPHTHALMIC ARTICLES MADE FROM CELLULOSE ESTER COMPOSITIONS HAVING HIGH TOUGHNESS AND DIMENSIONAL STABILITY EASTMAN CHEMICAL COMPANY (US) 2022-10-13 WO claimed
CN-110662746-B Compounds as orally administered prodrugs of beta-lactamase inhibitors, pharmaceutical compositions thereof and use for treating bacterial infections 阿里萨制药有限公司 2022-08-19 CN claimed
EP-0287416-B1 Process for the manufacture of masticated polyvinyl butyral for the bonding of a supporting bed to a screen, and products obtained SAINT GOBAIN VITRAGE (FR) 1994-07-27 EP claimed
US-5187217-A Reacting butyral with a Polyvinyl Alcohol having 98% hydrolysis and a viscosity of at least 50 cP to obtain hydroxylation of 23 to 25% using an acid catalyst, plasticizer and emulsifier SAINT-GOBAIN VITRAGE (FR) 1993-02-16 US claimed
EP-4368686-B1 LUBRICITY IMPROVER COMPOSITION FOR FUEL OIL AND USE THEREOF CHINA PETROLEUM & CHEM CORP (CN) 2026-05-27 EP disclosed
US-20260069734-A1 FRESHENING COMPOSITIONS COMPRISING CONTROLLED RELEASE MODULATORS ARYLESSENCE INC (US) 2026-03-12 US disclosed
US-20260021190-A1 GLUCOSE-RESPONSIVE INSULIN CONJUGATES COMPRISING A PENTA-VALENT SUGAR CLUSTER FOR TREATMENT OF DIABETES MERCK SHARP & DOHME LLC (US) 2026-01-22 US disclosed
US-12521455-B2 Kisspeptin receptor (KISS1R) targeted therapeutics and uses thereof RADIONETICS ONCOLOGY, INC. (US) 2026-01-13 US disclosed
US-12522671-B2 Paramylon-based resin, molding material, molded body, and method for producing paramylon-based resin NEC CORPORATION (JP) 2026-01-13 US disclosed
WO-2025217074-A1 KISSPEPTIN RECEPTOR (KISS1R) TARGETED THERAPEUTICS AND USES THEREOF RADIONETICS ONCOLOGY, INC. (US) 2025-10-16 WO disclosed
EP-0121383-B1 BIS-ESTERS OF DICARBOXYLIC ACIDS WITH AMOXICILLIN AND CERTAIN HYDROXYMETHYLPENICILLANATE 1,1-DIOXIDES PFIZER INC. (US) 1986-05-07 EP disclosed
EP-0083484-B1 1,1-ALKANEDIOL DICARBOXYLATE LINKED ANTIBACTERIAL AGENTS PFIZER INC. (US) 1986-02-19 EP disclosed
EP-0121383-A1 Bis-esters of dicarboxylic acids with amoxicillin and certain hydroxymethylpenicillanate 1,1-dioxides PFIZER INC. (US) 1984-10-10 EP disclosed
US-4462934-A BACTERICIDES FROM PENICILLINS AND PENICILLINASE INHIBITORS PFIZER INC. (US) 1984-07-31 US disclosed
US-4457924-A PENICILLINS, OXAPENICILLINS, BETA-LACTAMASE INHIBITORS PFIZER, INC. (US) 1984-07-03 US disclosed
US-4410461-A Production of benzylic esters ASHLAND OIL, INC. (US) 1983-10-18 US disclosed
EP-0083484-A1 1,1-Alkanediol dicarboxylate linked antibacterial agents PFIZER INC. (US) 1983-07-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260021190-A1 GLUCOSE-RESPONSIVE INSULIN CONJUGATES COMPRISING A PENTA-VALENT SUGAR CLUSTER FOR TREATMENT OF DIABETES INSR, GPR119, GLP1R ALDH1A1 2398/4885MAPK1 3293/4885L3MBTL1 2640/4885
US-20260069734-A1 FRESHENING COMPOSITIONS COMPRISING CONTROLLED RELEASE MODULATORS FFAR1, FFAR2, FFAR3 ALDH1A1 697/4885MAPK1 3240/4885L3MBTL1 4774/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.